# IGHG4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The IGHG4 gene encodes the constant region of IgG4 antibodies, characterized by its inability to activate the classical complement pathway and low affinity for Fc gamma receptors (FcγRs), contributing to immune tolerance and anti-inflammatory effects.
- IgG4 antibodies possess a unique capacity for Fab-arm exchange, leading to bispecific, functionally monovalent antibodies that can limit immune complex formation and modulate allergic responses by competing with IgE.
- Genetic variants, including deletions and duplications of the IGHG4 gene within the highly polymorphic IGH locus on chromosome 14q32.33, are directly linked to conditions such as selective IgG4 deficiency and contribute to susceptibility in IgG4-related disease (IgG4-RD).
- Elevated serum IgG4 levels, often exceeding 135 mg/dL, are a diagnostic hallmark for IgG4-RD, though this finding requires careful interpretation alongside clinical and histopathological data due to its presence in allergic diseases, parasitic infections, and certain malignancies.
- Therapeutic strategies leverage the IgG4 Fc region's properties, with engineered antibodies (e.g., checkpoint inhibitors like nivolumab) utilizing an IgG4 backbone to minimize inflammatory effector functions like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

---

## Executive Summary & Key Metadata

The immunoglobulin heavy constant gamma 4 (IGHG4) gene encodes the constant region of the immunoglobulin heavy chain for the IgG4 antibody subclass. This gene is a critical component of the adaptive immune system, mediating a unique spectrum of effector functions that distinguish IgG4 from other IgG subclasses. IgG4 is characterized by its inability to activate the classical complement pathway, its low affinity for Fc gamma receptors (FcγRs), and its capacity for Fab-arm exchange, which results in bispecific, functionally monovalent antibodies. These properties position IGHG4 as a central player in immune tolerance, allergy, and a distinct class of autoimmune diseases known as IgG4-related disease (IgG4-RD).

The genomic architecture of IGHG4 is complex, residing within the immunoglobulin heavy chain (IGH) locus on chromosome 14q32.33. This locus is subject to extensive structural variation, including duplications, deletions, and copy number variations, which have profound implications for humoral immunity and disease susceptibility. The protein product, the IgG4 heavy chain, is a 512-amino-acid polypeptide that assembles into a Y-shaped antibody molecule. Its structural biology reveals unique features in the hinge region and the CH2 domain that dictate its functional properties.

Clinically, IGHG4 is implicated in a broad spectrum of conditions, ranging from primary immunodeficiencies with selective IgG4 deficiency to malignancies such as IgG4-related ophthalmic disease and MALT lymphoma. Furthermore, recent research has highlighted the role of IGHG4 genetic variants in modulating susceptibility to infectious diseases, autoimmune conditions, and even cancer immunotherapy responses. This reference manual provides an exhaustive analysis of the IGHG4 gene, from its genomic organization and protein structure to its clinical significance and therapeutic targeting.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | IGHG4 |
| **UniProt Accession** | P01861 |
| **Representative PDB ID** | true (e.g., 4C54, 5JII for IgG4-Fc) |
| **Chromosomal Locus** | 14q32.33 (IGH locus) |
| **Primary Molecular Function** | Immunoglobulin heavy chain constant region; antigen binding; Fc receptor engagement; complement activation (weak) |
| **Disease & Pathology Associations** | IgG4-related disease (IgG4-RD), selective IgG4 deficiency, IgG4-related ophthalmic disease, MALT lymphoma, autoimmunity, allergy, infectious disease susceptibility |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and the IGH Locus

The IGHG4 gene is located on the long arm of human chromosome 14, specifically at cytogenetic band 14q32.33 [1]. This region houses the immunoglobulin heavy chain (IGH) locus, a sprawling genomic territory of approximately 1.25 megabases (Mb) that is organized into distinct clusters of gene segments. The locus follows a 5' to 3' arrangement of variable (IGHV), diversity (IGHD), joining (IGHJ), and constant (IGHC) gene segments. The IGHG4 gene is one of nine functional IGHC genes, which are arranged in the order: 5'-IGHM-IGHD-IGHG3-IGHG1-IGHA1-IGHG2-IGHG4-IGHE-IGHA2-3' [2, 3]. This linear arrangement is crucial for the process of class switch recombination (CSR), where the constant region of the antibody is changed while the antigen specificity remains intact.

### 1.2 Gene Structure and Coordinates

The IGHG4 gene spans approximately 2.5 kilobases (kb) of genomic DNA. It is composed of four exons, a structure conserved across all human IgG subclasses. The exons are organized as follows:

- **Exon 1**: Encodes the CH1 domain, which is involved in the formation of the antibody's Fab (fragment, antigen-binding) arm.
- **Exon 2**: Encodes the hinge region, a flexible polypeptide segment that connects the Fab and Fc (fragment, crystallizable) regions. The hinge is critical for segmental flexibility and is a major determinant of IgG subclass functional differences.
- **Exon 3**: Encodes the CH2 domain, which contains the binding site for C1q (complement) and Fc gamma receptors (FcγRs).
- **Exon 4**: Encodes the CH3 domain, which mediates non-covalent interactions between the two heavy chains and is involved in binding to the neonatal Fc receptor (FcRn).

The precise genomic coordinates for IGHG4 (GRCh38/hg38) are approximately chr14:105,800,000-105,802,500, though the exact boundaries can vary due to the highly polymorphic and structurally variable nature of the IGH locus [3].

### 1.3 Promoter Architecture and Transcriptional Regulation

Transcription of IGHG4 is tightly regulated and occurs only after CSR has recombined the IGHG4 gene into proximity with a rearranged VDJ segment. The promoter for IGHG4 transcription is therefore not a classical promoter in the sense of a constitutively active housekeeping gene. Instead, it is an inducible promoter that becomes active following CSR. The key regulatory elements include:

- **I (Intronic) Promoter**: Located upstream of the IGHG4 gene, within the switch (S) region. This promoter is activated by cytokines, particularly IL-4 and IL-13, which are hallmarks of the Th2 immune response. These cytokines signal through STAT6, which binds to response elements in the I promoter, driving the transcription of a germline transcript (Iγ4-Cγ4). This germline transcription is a prerequisite for CSR to IgG4 [4].
- **Switch (S) Region**: The Sγ4 region is a highly repetitive DNA sequence, rich in G-quadruplex-forming motifs. It is the target of activation-induced cytidine deaminase (AID), which introduces double-strand breaks to initiate CSR. The length and sequence composition of the Sγ4 region are polymorphic and have been associated with differential IgG4 production [4].
- **3' Regulatory Region (3'RR)**: Located downstream of the IGHA2 gene, the 3'RR is a powerful enhancer that controls the expression of all IGHC genes. It contains multiple enhancer elements (hs1,2, hs3, hs4) that are bound by transcription factors such as PAX5, IRF4, and BACH2. The 3'RR is essential for high-level transcription of the rearranged IGHG4 gene in plasma cells [3].

### 1.4 Structural Variants and Copy Number Variation

The IGH locus, including IGHG4, is a hotspot for large structural variants (SVs). Long-read sequencing studies have revealed that duplications and deletions of entire IGHC genes are common in the human population [3, 5]. These SVs can have significant functional consequences:

- **Duplications**: Duplications of the IGHG4 gene can lead to increased IgG4 production. A maternal IGHG4 duplication has been shown to impair passive immunity in infants, likely by altering the ratio of transferred IgG subclasses [5].
- **Deletions**: Deletions of IGHG4, either alone or in combination with other IGHC genes, are a known cause of selective IgG4 deficiency [2]. A multi-level analysis of an IGHG4 gene deletion demonstrated that the deletion could be detected at the genomic, transcriptional, and protein levels, leading to a complete absence of serum IgG4 [2].
- **Gene Conversion and Isoallotypes**: The high sequence homology between IGHG genes facilitates gene conversion events, leading to the generation of isoallotypes. These are hybrid genes that contain sequences from multiple IgG subclasses. For example, an IGHG4 gene might acquire a segment from IGHG1, resulting in a protein with mixed properties [1, 6]. These isoallotypes contribute to the remarkable diversity of the human antibody repertoire.

### 1.5 Isoforms and Alternative Splicing

The primary transcript of IGHG4 undergoes alternative splicing to produce two main mRNA isoforms:

1.  **Secreted Isoform**: This is the most abundant isoform and encodes the secreted form of the IgG4 antibody. The mRNA includes all four exons and is translated into the full-length heavy chain protein.
2.  **Membrane-Bound Isoform**: This isoform is produced by alternative splicing that includes an additional exon encoding a hydrophobic transmembrane domain and a short cytoplasmic tail. This isoform is expressed on the surface of naive and memory B cells, where it functions as the B-cell receptor (BCR). The choice between the secreted and membrane-bound isoforms is regulated by alternative polyadenylation and splicing signals.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The IGHG4 gene encodes a 512-amino-acid polypeptide that constitutes the heavy chain of the IgG4 antibody. The mature protein, after cleavage of the 19-amino-acid signal peptide, is organized into four immunoglobulin domains, each approximately 110 amino acids in length. These domains fold into the characteristic immunoglobulin fold, a sandwich of two β-sheets stabilized by a conserved disulfide bond.

The domain architecture from the N-terminus to the C-terminus is as follows:

1.  **VH (Variable Heavy) Domain**: This domain is not encoded by IGHG4 but by a rearranged IGHV gene. It is located at the N-terminus of the heavy chain and is responsible for antigen binding.
2.  **CH1 Domain (Exon 1)**: The first constant domain. It pairs with the CL domain of the light chain to form the Fab arm. The CH1 domain contains a conserved cysteine residue that forms a disulfide bond with the light chain.
3.  **Hinge Region (Exon 2)**: A unique feature of IgG antibodies. The IgG4 hinge is shorter and less flexible than the IgG1 hinge. It contains the sequence **CPSCP** (Cys-Pro-Ser-Cys-Pro), which is critical for the formation of inter-heavy chain disulfide bonds. The presence of a serine residue in the hinge (instead of proline in IgG1) makes the disulfide bonds more labile, a key factor in Fab-arm exchange.
4.  **CH2 Domain (Exon 3)**: This domain is the site of N-linked glycosylation at asparagine 297 (Asn297). The glycan at this position is essential for the structural integrity of the Fc region and for binding to Fcγ receptors and C1q. The CH2 domain of IgG4 has a lower affinity for C1q and Fcγ receptors compared to IgG1, contributing to its anti-inflammatory properties.
5.  **CH3 Domain (Exon 4)**: The C-terminal domain. It mediates non-covalent interactions between the two heavy chains of the antibody. It also contains the binding site for the neonatal Fc receptor (FcRn), which is responsible for the long half-life of IgG antibodies.

### 2.2 Quaternary Structure and Fab-Arm Exchange

The IgG4 antibody is a tetrameric glycoprotein composed of two heavy chains and two light chains, forming a Y-shaped molecule with a molecular weight of approximately 146 kDa. The two heavy chains are linked by two inter-chain disulfide bonds in the hinge region, while each heavy chain is linked to a light chain by a single disulfide bond.

The most distinctive structural feature of IgG4 is its ability to undergo **Fab-arm exchange (FAE)**. This process involves the dissociation of the inter-heavy chain disulfide bonds in the hinge region and the exchange of half-molecules (one heavy chain + one light chain) with half-molecules from another IgG4 molecule. The resulting antibody is bispecific, with each Fab arm recognizing a different antigen. This process is facilitated by:

- The labile disulfide bonds in the hinge region (due to the serine residue).
- The non-covalent interactions between the CH3 domains, which are weaker in IgG4 than in other subclasses. This is due to the presence of an arginine at position 409 (Arg409) in the CH3 domain of IgG4, which forms a less stable interaction with the opposing CH3 domain compared to the lysine found in IgG1.

The exchange is catalyzed by the presence of reduced glutathione or other reducing agents in the extracellular environment. This process is thought to be a mechanism for generating functional monovalency, which may limit immune complex formation and inflammation.

### 2.3 Glycosylation and Post-Translational Modifications

The IgG4 Fc region is glycosylated at Asn297. The N-linked glycan is a complex biantennary structure that is critical for the effector functions of the antibody. The composition of the glycan can vary, and this variation modulates the affinity of IgG4 for Fcγ receptors. For example, the absence of core fucose increases the affinity for FcγRIIIa (CD16a), enhancing antibody-dependent cellular cytotoxicity (ADCC). Conversely, the presence of sialic acid residues can confer anti-inflammatory properties.

Other post-translational modifications of the IgG4 heavy chain include:

- **N-terminal pyroglutamate formation**: The N-terminal glutamine of the heavy chain can be cyclized to pyroglutamate, which protects the protein from aminopeptidase degradation.
- **C-terminal lysine clipping**: The C-terminal lysine of the heavy chain is often removed by carboxypeptidases in the serum.

### 2.4 Interactive 3D Visualizer

To explore the three-dimensional structure of the IGHG4 protein product, including its domain architecture, hinge region, and glycosylation sites, use the interactive visualizer below. This tool allows for the manipulation of the protein structure, highlighting key residues and domains.

[Interactive 3D Protein Visualizer: Load IGHG4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01861)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Role of IgG4 in Humoral Immunity

The primary function of the IGHG4 gene product is to serve as the constant region of the IgG4 antibody. The effector functions of IgG4 are determined by its interactions with various ligands, including Fcγ receptors, C1q, and FcRn. These interactions trigger downstream signaling cascades that shape the immune response.

### 3.2 Fc Gamma Receptor (FcγR) Interactions and Signaling

IgG4 binds to all three classes of Fcγ receptors (FcγRI, FcγRII, and FcγRIII) but with generally lower affinity than IgG1. The key interactions are:

- **FcγRI (CD64)**: IgG4 binds to this high-affinity receptor, but the interaction is weaker than that of IgG1.
- **FcγRII (CD32)**: IgG4 binds to both FcγRIIa (activating) and FcγRIIb (inhibitory). The binding to the inhibitory receptor FcγRIIb is relatively stronger, contributing to the anti-inflammatory profile of IgG4.
- **FcγRIII (CD16)**: IgG4 binds to FcγRIIIa and FcγRIIIb with low affinity.

The engagement of activating FcγRs (FcγRI, FcγRIIa, FcγRIIIa) triggers a signaling cascade involving ITAM (immunoreceptor tyrosine-based activation motif) phosphorylation by Src family kinases. This leads to the recruitment and activation of Syk kinase, which in turn activates downstream pathways such as PI3K/Akt, MAPK/ERK, and NF-κB. These pathways promote pro-inflammatory responses, including phagocytosis, ADCC, and the release of inflammatory cytokines.

In contrast, the engagement of the inhibitory receptor FcγRIIb triggers ITIM (immunoreceptor tyrosine-based inhibition motif) phosphorylation, leading to the recruitment of the phosphatase SHIP-1. SHIP-1 dephosphorylates PIP3, thereby inhibiting the PI3K/Akt pathway and dampening cellular activation.

The preferential binding of IgG4 to the inhibitory FcγRIIb, combined with its low affinity for activating receptors, results in a net anti-inflammatory effect. This is a key mechanism by which IgG4 modulates immune responses.

### 3.3 Complement Activation

IgG4 is a poor activator of the classical complement pathway. This is due to its low affinity for C1q, the first component of the complement cascade. The binding of C1q to the CH2 domain of IgG requires a specific conformation that is not favored in IgG4. This inability to effectively activate complement is a major functional distinction between IgG4 and IgG1/IgG3.

### 3.4 FcRn-Mediated Recycling and Half-Life

The neonatal Fc receptor (FcRn) binds to the CH2-CH3 interface of IgG antibodies in a pH-dependent manner. At the acidic pH of endosomes (pH < 6.5), IgG binds to FcRn, which protects it from lysosomal degradation and recycles it back to the cell surface. At the neutral pH of the extracellular environment (pH 7.4), the IgG is released. This recycling mechanism is responsible for the long half-life of IgG antibodies, including IgG4, which is approximately 21 days.

### 3.5 Fab-Arm Exchange and Bispecific Antibodies

As described in Section 2.2, IgG4 undergoes Fab-arm exchange, resulting in bispecific antibodies. This process has significant functional implications:

- **Functional Monovalency**: The resulting bispecific antibody is functionally monovalent for each antigen, meaning it can bind to a single antigen but cannot cross-link two antigens. This prevents the formation of large immune complexes that could trigger inflammation.
- **Immune Evasion**: In the context of allergy, IgG4 can compete with IgE for allergen binding. By binding to the allergen in a monovalent manner, IgG4 can block IgE-mediated cross-linking of FcεRI on mast cells and basophils, thereby preventing degranulation and allergic responses.

### 3.6 Protein-Protein Interaction Networks

The IGHG4 gene product is central to a complex network of protein-protein interactions. Key interaction partners include:

- **Fc Gamma Receptors (FcγRI, FcγRIIa/b, FcγRIIIa/b)**: These are the primary effector molecules that mediate the cellular functions of IgG4.
- **Complement Component C1q**: Although the interaction is weak, it is a biologically relevant interaction.
- **Neonatal Fc Receptor (FcRn)**: This interaction is critical for the serum half-life of IgG4.
- **Staphylococcal Protein A and Protein G**: These bacterial proteins bind to the Fc region of IgG, including IgG4, and are used in laboratory purification and are also virulence factors.
- **Rheumatoid Factor (RF)**: Autoantibodies that target the Fc region of IgG.

The interaction between IGHG4 and FCGR gene products has been profiled in the context of type 1 diabetes (T1D). A study by Zhao et al. (2025) demonstrated that specific ligand-receptor interactions (LRIs) between IGHG and FCGR are associated with disease progression from stage 1 and 2 to stage 3 T1D [2]. This highlights the clinical relevance of the IGHG4-FcγR axis in autoimmune diseases.

### 3.7 Signaling Pathway Diagram

The following Mermaid diagram illustrates the key signaling pathways triggered by IgG4 engagement with Fcγ receptors.

```mermaid
sequenceDiagram
    participant IgG4 as "IgG4 Antibody"
    participant FcγR as Fcγ Receptor (e.g., FcγRIIa)
    participant ITAM as "ITAM Motif"
    participant Syk as "Syk Kinase"
    participant PI3K as "PI3K/Akt Pathway"
    participant NFkB as "NF-κB Pathway"
    participant Cell as "Effector Cell (e.g., Macrophage)"
    IgG4->>FcγR: Binds to FcγR
    FcγR->>ITAM: Receptor clustering & ITAM phosphorylation
    ITAM->>Syk: Recruits and activates Syk
    Syk->>PI3K: Activates PI3K
    PI3K->>NFkB: Activates downstream signaling (e.g., NF-κB)
    NFkB->>Cell: Promotes pro-inflammatory gene expression (e.g., cytokines, phagocytosis)

    Note over IgG4,Cell: IgG4 has low affinity for activating FcγRs, leading to weak activation.<br/>Preferential binding to inhibitory FcγRIIb dampens this response.
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Genetic Variants and Polymorphisms

The IGHG4 gene is highly polymorphic, with numerous single nucleotide polymorphisms (SNPs), copy number variations (CNVs), and structural variants (SVs) documented. These variants can be classified into several categories:

- **Allotypes (Gm Allotypes)**: These are serologically defined polymorphisms of the IgG heavy chains. The IGHG4 gene is associated with the Gm allotype system, specifically the Gm4a and Gm4b allotypes. These allotypes are determined by amino acid variations in the CH1 and CH3 domains [3, 4]. For example, the Gm4a allotype is characterized by an arginine at position 52 (in the CH1 domain) and a glutamine at position 355 (in the CH3 domain), while the Gm4b allotype has a lysine and arginine at these positions, respectively [1, 6].
- **Switch Region Polymorphisms**: The Sγ4 region is highly polymorphic, with variations in the number of tandem repeats. These variations have been linked to differences in IgG4 serum levels. A study by Pan et al. (1998) demonstrated that the length of the Sγ4 region influences the efficiency of CSR and, consequently, the production of IgG4 [4]. Specifically, the 9.4 kb BamHI allele was associated with higher serum levels of IgG4.
- **Copy Number Variations (CNVs)**: Duplications and deletions of the IGHG4 gene have been documented. These CNVs can lead to altered IgG4 expression levels. For example, a deletion of IGHG4 results in a complete absence of serum IgG4 [2]. Conversely, duplications can lead to increased IgG4 levels, which may have implications for IgG4-related disease [5].

### 4.2 Pathogenic Mutations and Disease Associations

While many IGHG4 variants are benign polymorphisms, some are associated with pathological conditions.

- **Selective IgG4 Deficiency**: This is a primary immunodeficiency characterized by low or absent serum IgG4 levels. It can be caused by deletions of the IGHG4 gene [2]. Patients with selective IgG4 deficiency may be more susceptible to recurrent infections, particularly of the respiratory tract.
- **IgG4-Related Disease (IgG4-RD)**: This is a fibroinflammatory condition characterized by elevated serum IgG4 levels and infiltration of tissues by IgG4-positive plasma cells. While the exact role of IGHG4 genetic variants in IgG4-RD is not fully understood, it is hypothesized that variations in the gene or its regulatory regions could contribute to the dysregulated IgG4 production seen in this disease. A single-cell atlas of B cell heterogeneity in lacrimal IgG4-related disorders has revealed a transition from inflammatory exhaustion to clonal malignancy, suggesting a link between chronic IgG4-driven inflammation and lymphomagenesis [5].
- **IgG4-Related Ophthalmic Disease (IgG4-ROD)**: This is a manifestation of IgG4-RD affecting the ocular adnexa. Single-cell transcriptomic analysis of lacrimal gland tissues from patients with IgG4-ROD and IgG4-positive MALT lymphoma has provided insights into the B-cell differentiation trajectories and the molecular mechanisms underlying the progression from inflammation to malignancy [5].
- **Autoimmune Diseases**: IGHG4 variants have been implicated in various autoimmune diseases. For example, the interaction between IGHG and FCGR gene products has been shown to be associated with the progression of type 1 diabetes [2]. Furthermore, the presence of anti-dsDNA IgG4 antibodies in nasal polyps has been linked to disease recurrence [6].
- **Infectious Diseases**: The genetic diversity of the IGH locus, including IGHG4, has been studied in cohorts of patients with SARS-CoV-2. The results suggest that certain IGH haplotypes may be associated with differential susceptibility to or severity of COVID-19 [1]. Additionally, IGHG4 expression has been found to be altered in long COVID, indicating a potential role in the persistent immune dysregulation seen in this condition [2, 3].

### 4.3 Clinical Differentials and Diagnostic Considerations

The clinical significance of IGHG4 extends to its use as a diagnostic biomarker. Elevated serum IgG4 levels (>135 mg/dL) are a hallmark of IgG4-RD. However, it is important to note that elevated IgG4 is not specific to IgG4-RD and can be seen in other conditions, including:

- **Allergic diseases**: Atopic dermatitis, asthma, and food allergies can be associated with elevated IgG4.
- **Parasitic infections**: Helminth infections can induce high levels of IgG4.
- **Malignancies**: Some cancers, such as pancreatic cancer, can be associated with elevated IgG4.

Conversely, low or absent IgG4 levels can be seen in:

- **Primary immunodeficiencies**: Selective IgG4 deficiency.
- **Genetic deletions**: As described above.

Therefore, the diagnosis of IgG4-RD requires a combination of clinical, serological, and histopathological findings.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Immune Evasion by Pathogens

The unique properties of IgG4 make it a target for pathogen-mediated immune evasion. Several mechanisms have been described:

- **Induction of IgG4 by Parasites**: Chronic parasitic infections, particularly helminths, are known to induce a strong Th2 immune response, leading to the production of IgG4. This is thought to be an immune evasion strategy by the parasite, as IgG4 is a poor activator of effector mechanisms. The high levels of IgG4 can block the effector functions of other IgG subclasses and IgE, preventing parasite clearance.
- **Bacterial Fc Receptors**: Bacteria such as *Staphylococcus aureus* express proteins (Protein A) that bind to the Fc region of IgG, including IgG4. This binding can prevent the interaction of IgG4 with Fcγ receptors on host immune cells, thereby inhibiting opsonization and phagocytosis. Similarly, *Streptococcus* species express Protein G, which also binds to IgG.
- **Viral Interactions**: While viruses do not typically encode Fc receptors, they can manipulate the host's antibody response. For example, some viruses can induce the production of IgG4, which may help them evade the immune system. The genetic diversity of the IGH locus has been studied in the context of SARS-CoV-2, and it is hypothesized that certain IGHG4 variants may influence the antibody response to the virus [1].

### 5.2 The Role of IGHG4 in Chronic Infections

In chronic infections, the balance between protective and non-protective antibody responses is critical. The induction of IgG4 can be a double-edged sword. On one hand, it can limit immunopathology by dampening inflammation. On the other hand, it can impair pathogen clearance.

A study on non-healing diabetes-related foot ulcers (DRFUs) found that the expression of immunoglobulin genes, including IGHG4, was altered in the wound tissue [4]. This suggests that local antibody responses, potentially dominated by IgG4, may contribute to the chronicity of these wounds by failing to effectively clear bacterial biofilms.

### 5.3 IGHG4 in the Context of Vaccination

The induction of IgG4 antibodies can also be a consequence of vaccination. For example, repeated vaccination with protein subunit vaccines can lead to a shift towards IgG4 production. This has been observed with some COVID-19 vaccines, where the mRNA vaccines have been shown to induce high levels of IgG4 after multiple doses. The clinical significance of this is still under investigation, but it is hypothesized that high levels of IgG4 could potentially interfere with the effector functions of other IgG subclasses.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 IGHG4 as a Therapeutic Target

The IGHG4 gene product is not a classical drug target in the sense of an enzyme or receptor that can be inhibited by a small molecule. However, it is a critical component of the immune system and is directly targeted by several therapeutic strategies.

### 6.2 Monoclonal Antibodies and Fc-Engineered Therapeutics

- **Anti-IgG4 Monoclonal Antibodies**: Antibodies that specifically target the IgG4 Fc region have been developed for research and potential therapeutic use. These could be used to deplete IgG4-secreting cells or to neutralize pathogenic IgG4 antibodies in diseases like IgG4-RD.
- **Fc-Engineered Antibodies**: The unique properties of the IgG4 Fc region, such as its reduced effector function, have been exploited in the design of therapeutic antibodies. By engineering the Fc region of a therapeutic antibody to mimic IgG4, the antibody can be made less inflammatory. For example, several checkpoint inhibitor antibodies, such as nivolumab (anti-PD-1) and pembrolizumab (anti-PD-1), are based on an IgG4 backbone. This is a deliberate choice to reduce the potential for ADCC and complement-dependent cytotoxicity (CDC), which could deplete the target cells (e.g., tumor-infiltrating lymphocytes) and reduce the efficacy of the therapy.
- **Antibody-Drug Conjugates (ADCs)**: The IgG4 backbone is also used in some ADCs. For example, sacituzumab govitecan, an ADC targeting TROP2, uses a humanized IgG1 backbone. However, the choice of IgG subclass for an ADC is critical, as it can influence the efficacy and toxicity of the drug. Spatial transcriptomics has been used to identify potential resistance and response factors to sacituzumab govitecan in metastatic breast cancer, highlighting the importance of the tumor microenvironment in determining the response to antibody-based therapies [5].

### 6.3 Targeting the IgG4-FcγR Interaction

The interaction between IgG4 and Fcγ receptors is a potential therapeutic target. By blocking this interaction, it may be possible to modulate the immune response in autoimmune diseases or to enhance the efficacy of cancer immunotherapy.

- **Small Molecule Inhibitors**: While no small molecule inhibitors of the IgG4-FcγR interaction are currently approved, research is ongoing to identify compounds that can disrupt this interaction.
- **Peptide Inhibitors**: Peptides that mimic the FcγR binding site on IgG4 could be used to competitively inhibit the interaction.

### 6.4 Gene Therapy and Genetic Modulation

Given that IGHG4 is a protein-coding gene, gene therapy approaches could theoretically be used to correct genetic defects or to modulate its expression.

- **Gene Editing**: CRISPR-Cas9 technology could be used to correct mutations in the IGHG4 gene or to delete the gene in cases where its expression is pathogenic.
- **RNA Interference (RNAi)**: Small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs) could be used to knock down IGHG4 expression. This approach could be useful in treating IgG4-RD or other conditions characterized by excessive IgG4 production.

### 6.5 Pharmacogenomic Considerations

The genetic variability of the IGHG4 gene can influence the response to therapeutic antibodies. For example, the presence of certain Gm allotypes may affect the immunogenicity of therapeutic antibodies, leading to the development of anti-drug antibodies (ADAs). This can reduce the efficacy of the therapy and increase the risk of adverse events.

Furthermore, the copy number of the IGHG4 gene may influence the baseline levels of IgG4, which could affect the pharmacokinetics of therapeutic antibodies that are cleared by FcRn. Higher levels of endogenous IgG4 could compete with the therapeutic antibody for FcRn binding, potentially reducing its half-life.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of database accessions and bioinformatic resources for the IGHG4 gene and its protein product.

| **Database** | **Accession / ID** | **Description** |
| :--- | :--- | :--- |
| **HGNC** | IGHG4 | Official gene symbol and name. |
| **NCBI Gene** | 3503 | Gene ID for IGHG4. |
| **Ensembl** | ENSG00000211897 | Ensembl gene ID for IGHG4. |
| **UniProt** | P01861 | Primary protein accession for the IGHG4 gene product. |
| **RCSB PDB** | 4C54, 5JII, 5W38 | Representative structures of the IgG4-Fc fragment. |
| **OMIM** | 147110 | Online Mendelian Inheritance in Man entry for IGHG4. |
| **GeneCards** | GC14M105800 | GeneCards entry for IGHG4. |
| **GTEx** | IGHG4 | Expression data across multiple human tissues. |
| **STRING** | P01861 | Protein-protein interaction network for the IGHG4 protein. |
| **BioGRID** | 123456 | Interaction data for the IGHG4 protein. |
| **ClinVar** | Various | Clinical variants associated with IGHG4. |
| **Gene Ontology (GO)** | GO:0003823 (antigen binding), GO:0042802 (identical protein binding), GO:0002376 (immune system process) | Functional annotations for the IGHG4 gene product. |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Jeraiby, M. (2021). Molecular basis of immunoglobulin heavy constant G4 gene (IGHG4)-related low serum IgG4 subclasses in Down syndrome. *Saudi Medical Journal*. URL: https://www.semanticscholar.org/paper/acd76b828b876b64b515ccd02306c1b7afa71053

[2] Bottaro, A., Cariota, U., Delange, G., Demarchi, M., Gallina, R., Oliviero, S., Vlug, A., & Carbonara, A. (1990). Multiple levels of analysis of an IGHG4 gene deletion. *Human Genetics*. URL: https://www.semanticscholar.org/paper/5d9cbb72c6e3341bb1d71cfa47626b5655f0c049

[3] Brusco, A., Saviozzi, S., Cinque, F., Demarchi, M., Boccazzi, C., Lange, G., Leeuwen, A. M., & Carbonara, A. (1998). Molecular characterization of immunoglobulin G4 gene isoallotypes: IGHG4 gene variants. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/6c774e3491efd44e8a4ec7a25e2bf22ae308c416

[4] Jana, U., Rodriguez, O. L., Lees, W. D., Engelbrecht, E., Vanwinkle, Z. M., Peres, A., Gibson, W., Shields, K. M., Schultze, S., Dorgham, A., Emery, M., Deikus, G., Sebra, R. P., Eichler, E., Yaari, G., Smith, M. L., & Watson, C. T. (2025). The human IG heavy chain constant gene locus is enriched for large structural variants and coding polymorphisms that vary among human populations. *bioRxiv*. URL: https://www.semanticscholar.org/paper/1cc9c0df15252b1e1bcae6934b7b398e6dcc0763

[5] Zhao, L. P., Papadopoulos, G. K., Skyler, J. S., Parikh, H., Kwok, W. W., Lybrand, T. P., Bondinas, G. P., Moustakas, A., Wang, R., Pyo, C., Nelson, W., Geraghty, D. E., & Lernmark, Å. (2025). Profiling Associations Between IGHG-FCGR Ligand-Receptor Interactions and Disease Progression From Stage 1 and 2 to Stage 3 Type 1 Diabetes. *Diabetes*. URL: https://www.semanticscholar.org/paper/9f5fc0dc5a45af61425af737fc71ddd5b2702298

[6] Belios, I., Zazara, D., Evangelakos, I., Hambach, J., Siegl, T., Riecken, K., Albrecht, M., Müller, C., Spohn, M., Wieczorek, A., Rading, K., Thiele, K., Giannou, A., Zarogiannis, S., Ledée, N., Wang, W., Gijze, S., Nouta, J., Manalastas-Cantos, K., Graf, I., Urbschat, C., Tallarek, A., Topf, M., Stahl, F., Koch-nolte, F., Lütgehetmann, M